MedTrace Logo

Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

NCT03227562 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-08-04

No results posted yet for this study

Summary

Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency.

Subjects with acute anxiety symptoms (Hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. A check-up is made at D0, then the subjects begin the treatment (0.5mg risperidone). The same check-up is carried out on the following day (D1). The subjects fulfil a last check-up 12 week after the beginning of treatment (W12). During the D1-W12, the psychiatrist may changes the treatment.

Conditions

  • Anxiety State

Interventions

DRUG

RisperiDONE 0.5 MG

To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.

Sponsors & Collaborators

  • Marion Trousselard

    lead OTHER_GOV

Principal Investigators

  • Bertrand Lahutte · HIA Begin Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2021-09-01
Completion
2021-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03227562 on ClinicalTrials.gov